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Abstract
A large proportion of people suffering from Alzheimers disease (AD) worldwide 
are not receiving a timely diagnosis. The tools currently used to detect AD and monitor 
LWVSURJUHVVLRQDUHQRWVHQVLWLYHWRWKHSUHFOLQLFDOVWDJHVDQGODFNVSHFLÀFLW\IRUFRUUHFW
diagnosis. Available biomarkers show acceptable levels of sensitivity but remain little 
VSHFLÀFDQGQRWDFFHVVLEOHWRHYHU\RQH:HHPEUDFHWKHYLHZWKDWHQKDQFLQJFRJQLWLYH
assessment of AD should be a research priority. This Perspective paper focuses on issues 
which, to our view, have been preventing cognitive tests from meeting outstanding needs 








AD: Alzheimers Disease; CT: Computed Tomography; DLB: 
Dementia with Lewy Bodies; EEG: Electroencephalogram; 
ERP: Event-Related Potentials; Fmri: Functional Magnetic 
Resonance Imaging; FTD: Frontotemporal Dementia; ICOM: 
International Conference of Memory; MCI: Mild Cognitive 
Impairment; MRI: Magnetic Resonance Imaging; PD: Parkinsons 
Disease; PET: Positron Emission Tomography; SCD: Subjective   ?Ǣ ǣ  Ǣ ǣ ǦǢǣǦ
INTRODUCTION
Of the 46.8 million people suffering from dementia worldwide, 
only 20-50% are recognized and documented in primary care. 
This gap is certainly much greater in low and middle income 
countries, with some countries reporting that 90% of sufferers  ?Ǥ
of people suffering from dementia worldwide are not receiving 
a timely diagnosis, and thus have no access to treatment options 
or care. What factors drive the under diagnosis of dementia? 
What could researchers from cognitive neurosciences provide ǫ ?
bottlenecks of current diagnostic procedures and then discusses 
some approaches which may help improve the detection of AD 
and monitor its progression. 
The pit falls of current diagnostic tools for AD
As awareness about the initial symptoms of AD has grown 
dramatically over the last few years, people are approaching 
health services earlier. This is enabling the detection of cognitive 
impairments from the very early stages which could still be 
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ȋǤǤǡ ?Ǧȏ ?ȐȌ
after entering the objective stages (i.e., Mild Cognitive Impairment Ǧ  ȏ ?ȐȌǤ      
achievements, recent evidence suggests that these may already ȏ ?ǡ ?ǡ ?ȐǤ	ǡ
receiving a diagnosis of MCI is providing more problematic than     ȏ ?Ȑǡ         ǡ ȏ ?Ȑ      ? ǡ  ȏ ?Ȑǡ         ?   
approaches, research targets, and therapeutic pathways. To 
alleviate this tension and overcome some of these barriers 
a new generation of biomarkers for AD has been developed. ǡȏ ?ȐǡǤ
Limitations of current biomarkers of AD: AD is associated 
with severe brain atrophy which can be detected using structural ȋǡȌȋǤǤȏ ?ȐȌǤ
some brain regions, such as the hippocampus, are thought to be 
an early signature of AD, standardized values for brain volumes 
associated with AD that can be measured at a single time point do Ǥ	ȋǡȌ    ȋǡ    Ȍȏ ?ǡ ?ȐǤǡ       ?  ȏ ?ȐǤ
Molecular imaging technologies, using radiotracers targeting the 
deposit of beta-amyloid and astrocytosis have shown promising  ȏ ? ?ǡ ? ?ȐǤ     Ǧ  ?   ? ȏ ?ȐǤ      
a characteristic of AD but also of people with no evidence of 
cognitive decline, making these biomarkers unreliable for   ȏ ? ?ǡ ? ?ȐǤ ǡ   
debate as to whether amyloid or tau pathology is the key driver ȏ ? ?Ǧ ? ?ȐǤ
pathology still unclear, it remains very challenging to develop 
effective research strategies towards biomarker development 
and pharmacological targets. 
In addition to these theoretical limitations, biomarkers  Ǥ
procedures which are only available in secondary care or Ǥǡ
patients with AD in the future, the regular use of such techniques       ȏ ?ȐǤ  
could be gathered using affordable methodologies such as the 
ȋǤǤǡȋȌȌǤ       ȋǤǤǡǦǣ ? ? ?ǡǣ  ? ? ?Ȁ ? ? ?ȌǤ    
been associated with typical aging, depression and other age-        ?  ȋ   ȏ ? ?Ȑ ȌǤ      
cognitive tests which holds maker properties for AD with EEG       ȏ ? ?ȐǤ 
priority is to identify tests of cognitive function which hold such ǤǤ
Limitations of current cognitive markers of AD: Diagnosis 
and progression of AD are usually based on performance on 
batteries of cognitive tests assessing memory, reasoning, 
language, attention, etc. While these tests are sensitive to AD, 
they cannot distinguish AD from other disorders with similar 
cognitive symptoms (e.g. cognitive aging, depression or other Ȍȏ ?ȐǤ
repeated testing, thus masking decline or response to treatment       ȏ ?ȐǤ    
preventive initiatives the diagnostic goals have shifted towards 
the preclinical or subtle symptomatic stages. Most of the tests 
traditionally used to support the diagnosis of AD and monitor 
its progression fail at these stages of the disease. To overcome 
such a limitation composite scores have been introduced ȏ ? ?ǡ ? ?ȐǤ
which show different sensitivity trajectories to a wide range of 
neuropsychiatric disorders. Hence, composite scores may boost  ?Ǥ
understanding of the links between the pathophysiological           Ǥ      ?  
following section. 
Need for theory-driven markers of AD: Hippocampal-
related memory decline is one of the earliest symptoms referred 
by patients with AD. This long standing view has driven the 
development of cognitive and neuroimaging markers for AD      ȏ ?ǡ ? ?ȐǤ   ?ǡ  
the anterior sub-hippocampal areas (i.e. the entorhinal and Ȍȏ ? ?ȐǤǦ
better predictors of conversion from MCI to AD than hippocampal   ȏ ? ?ǡ ? ?ȐǤ        ?Ǧȏ ? ?ȐǤǡ ǡ 
unclear how these different structures of the Medial Temporal  ȋȌ   Ǥ    
selective brain damage to these structures show that the anterior Ǧ   Ǧ         Ǧ 
such events based on recollection rely on the hippocampus ȏ ? ?ȐǤǦǡǡ ?ȏ ? ?ȐǤȏ ? ?ǡ ? ?Ȑ         ǡ
early cognitive markers for AD should therefore focus on the  Ǧ     ȏ ? ?ȐǤ Ǧ        
normal aging as cognitive tests currently used for the diagnosis of ȋǤǤǡǢȏ ?ǡ ? ?ǡ ? ?ȐǤ
started to shed some light on novel memory tasks which seem to 
meet these and other criteria for a good test for AD.
Good markers to diagnose and monitor AD: Ideally, ȋȌ ?ǡȋȌǡȋȌ
sensitive to the education or cultural background of the assessed ǡȋȌǡ ȋȌ    Ǥ ǡ   ȋȌ               ȏ ?ȐǤ 
Central
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        ?       ?     ȏ ? ǡ ? ?ȐǤ 
is, some tests can be useful for screening in pre-symptomatic 
populations while others might help detect degree of impairment, 
progression, and response to treatment. To date available tests 
of cognitive function have been indistinctively used to serve all  Ǥ        
behind other molecular markers for AD with regard to their ȏ ? ?ȐǤ
Promising diagnostic tools for the pre-symptomatic 
stage of AD:  ?Ǧ
regions may cause symptoms which could be too subtle to be 
noticed by affected individuals or to cause concern (e.g., lack of ǡ    ǯ ȌǤ   
functions provide the building blocks of memory. Memory tests 
for AD have traditionally assessed higher level memory functions 
such as those responsible for integrating low level information ȋǤǤǡ ǦȌ    ȋǤǤǡ ȌǤ  ?      
only cause concern but also interfere with everyday life tasks. 
We have now learned more about the link between low level 
memory functions and their neural correlates within the MTL. 
What we need to improve is our understanding of the links 
between AD pathology and such subtle memory impairments.     Ǧ   
the sub-hippocampal regions may offer sensitive diagnostic 
tools for the detection of AD before manifest clinical symptoms Ǥ   Ǧ    
of words have shown to be impaired in patients in the pre-    ȏ ? ?ȐǤ Ǧ  
of intra-item associations such as combinations of colour and ȏ ? ?ȐǤ ?ȋǤǤȌ
been observed in prodromal stages of sporadic and familial AD ȏ ? ?ǡ ? ?ȐǤ
Testing Didic et al.s hypothesis: The recently developed  Ǧ   ȋȌ         ȏ ? ?ǡ ? ?ǡ ? ?ȐǤ           ȏ ? ?Ȑǡ       ȏ ? ?Ȑǡ     Ǧ ȋǤǤǡ 	ǡ ǡ ǡ Ȍ ȏ ? ?ȐǤ 	ǡ    ? ? ?Ǧ ?  ȏ ? ?ǡ ? ?Ȑǡ    ? ?      Ǥ  ǡ     
mutation carriers were observed in the absence of evidence of   ȏ ? ?ǡ ? ?ȐǤ         ȏ ? ?ǡ ? ?Ȑǡ   
preclinical stages of AD when tests of hippocampal functions are ȏ ? ?ǡ ? ?Ȑǡ
the hippocampus when performed by healthy younger subjects ȏ ? ?ȐǤ     Ǧ    ȏ ? ?ȐǤ  Ǥǡȏ ? ?Ȑ  Ǧ   Ǥ 
to methodological limitations of fMRI. We need to better map 
the intrinsic structure of the MTL to ascertain such involvement 
or lack thereof. Recently, Parra et al., (paper presented in   ? ? ? ?Ȍ     ȋȌ          ?ȋȌǤ
associative memory functions in the verbal domain relied on an 
gyrus. Atrophy of these regions accounted for discrepancies in 
performance between patients and controls. In contrast, poor ȋȌ
by atrophy of visual association areas found to be relevant in a ȏ ? ?ȐǤǡ
areas along the ventral visual stream which are known to feed Ǧ ȏ ? ?Ȑǡ    ?   Ǥ          ȏ ? ?ȐǤ ?
as they may be failed by patients suffering from a wider range of 
brain diseases.
Promising monitoring tools during the symptomatic 
stages of AD (phase from MCI to AD conversion): Based on  Ǥȏ ? ?Ȑǡ Ǧ   
the hippocampal stages of AD. This stage is characterized by  Ǧ  Ǧ ȋȌ  ǯȏ ? ?ȐǤ
At this stage patients show autobiographical and topographical 
memory loss which cause concern and therefore prompt them to 
seek help advice. The diagnosis of MCI commonly follows. Hence, 
MCI is the earliest stage of AD that available tests of episodic ȏ ? ?ǡ ? ?ȐǤǦ
are responsible for cognitive decline which alters everyday life 
functioning (e.g., being unable to remember where you left the  Ȍ ȏ ? ?ȐǤǦ 
could therefore provide valuable information about effectiveness 
of medication or treatments during the symptomatic stage of AD. 	ȏ ? ?ȐǤǡ    ȋǤǤ ǡ ǡ  Ǧ       ȏ ?ȐȌ 
useful to monitor cognitive decline in individuals diagnosed with 
MCI as well as to interpret functional decline. 
From theory-driven assessment to theory-driven 
interventions: With the advent of prevention initiative for AD, 
cognitive makers which meet the needs discussed above are of 
upmost priority. However, to date, no effective pharmacological  ?Ǥ
Previous pharmacological trials have only shown sub threshold   ǡ    ȏ ? ?ȐǤ       ?      ǡȋǤǤǡȌǡ
in rating procedures is not fully understood. There is a general 
consensus that improvement of cognitive scoring and rating 
procedures are required. Good tests of cognitive function cannot 
only inform pharmacological treatments but also provide theory 
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to develop non-pharmacological interventions. Some studies 
have shown that cognitive interventions can have a positive ȏ ? ?Ǧ ? ?ȐǤ ȋȌȏ ? ?Ǧ ? ?ȐǤ                 ȏ ? ?Ǧ ? ?ȐǤ      ?          
dementia and their family by giving educational support and   ȏ ? ?Ǧ ? ?ȐǤ  ǡ    ? Ǥ            Ǧ  
ÀǦ  Ǥ ȏ ? ?ȐǤ     ?    ȋǤǤǡǡȌǤǡȏ ? ?Ǧ ? ?ȐǤ
CONCLUSIONS        
currently delves into a prioritized set of needs leads us to present 
some recommendations which may be considered by future 
research strategies. ?Ǥ A new research pathway to map effective tests of 
cognitive function to progression of neuropathology in Ǥ
2.  ? ?Ǧ 
anatomical structure of the MTL and its vulnerability to 
AD-related amyloid and tau pathology. ?Ǥ Identifying suitable theory-driven memory tests to screen 
for, support the diagnosis, and monitor the progression of 
AD dementia.
4. Development of theory-driven cognitive interventions to 
aid the frail elderly and support those transiting through 
the continuum of AD.
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